Allergan PLC. (NYSE:AGN) announced a quarterly dividend on Friday, October 27th, RTT News reports. Shareholders of record on Friday, November 17th will be paid a dividend of 0.70 per share on Friday, December 15th. This represents a $2.80 dividend on an annualized basis and a yield of 1.63%. The ex-dividend date is Thursday, November 16th.
Allergan PLC. has a dividend payout ratio of 17.2% meaning its dividend is sufficiently covered by earnings. Equities research analysts expect Allergan PLC. to earn $16.18 per share next year, which means the company should continue to be able to cover its $2.80 annual dividend with an expected future payout ratio of 17.3%.
Shares of Allergan PLC. (NYSE AGN) opened at $171.82 on Wednesday. Allergan PLC. has a 12-month low of $169.61 and a 12-month high of $256.80. The company has a debt-to-equity ratio of 0.40, a current ratio of 1.18 and a quick ratio of 1.08. The firm has a market capitalization of $58,005.82, a P/E ratio of 11.31, a PEG ratio of 1.11 and a beta of 1.13.
Allergan PLC. (NYSE:AGN) last posted its quarterly earnings data on Wednesday, November 1st. The company reported $4.15 earnings per share for the quarter, beating the consensus estimate of $4.06 by $0.09. Allergan PLC. had a positive return on equity of 8.00% and a negative net margin of 47.27%. The company had revenue of $4.03 billion during the quarter, compared to analysts’ expectations of $4.04 billion. During the same period in the prior year, the business earned $3.32 earnings per share. Allergan PLC.’s revenue for the quarter was up 11.4% compared to the same quarter last year. sell-side analysts anticipate that Allergan PLC. will post 16.28 EPS for the current fiscal year.
Several equities research analysts have recently weighed in on AGN shares. Royal Bank Of Canada reissued a “buy” rating and issued a $285.00 price objective on shares of Allergan PLC. in a research report on Wednesday, September 6th. Credit Suisse Group set a $243.00 target price on Allergan PLC. and gave the company an “outperform” rating in a research note on Tuesday, October 17th. Citigroup Inc. cut their target price on Allergan PLC. from $280.00 to $240.00 and set a “buy” rating for the company in a research note on Thursday, October 19th. set a $231.00 target price on Allergan PLC. and gave the company a “hold” rating in a research note on Wednesday, November 1st. Finally, lowered Allergan PLC. from a “buy” rating to a “hold” rating in a research note on Wednesday, August 9th. One analyst has rated the stock with a sell rating, eleven have assigned a hold rating and twelve have assigned a buy rating to the stock. Allergan PLC. presently has an average rating of “Hold” and a consensus target price of $246.73.
Allergan PLC. announced that its board has authorized a stock repurchase plan on Monday, September 25th that allows the company to repurchase $2.00 billion in shares. This repurchase authorization allows the company to repurchase up to 2.8% of its shares through open market purchases. Shares repurchase plans are typically a sign that the company’s management believes its shares are undervalued.
TRADEMARK VIOLATION NOTICE: This news story was published by Week Herald and is the property of of Week Herald. If you are reading this news story on another domain, it was copied illegally and republished in violation of US & international copyright and trademark legislation. The legal version of this news story can be accessed at https://weekherald.com/2017/11/15/allergan-plc-agn-to-go-ex-dividend-on-november-16th.html.
Allergan PLC. Company Profile
Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.
Receive News & Ratings for Allergan PLC. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan PLC. and related companies with MarketBeat.com's FREE daily email newsletter.